Security key
98422T100
Xilio Therapeutics, Inc. - Common Stock, par value $0.0001 per share (XLO)
CUSIP: 98422T100
Q1 2026 13F Holders as of 31 Mar 2026
- Security type / class
- Equity / Common Stock, par value $0.0001 per share
- Shares outstanding
- 6,426,426
- Total 13F shares
- 650,389
- Share change
- -37,821,734
- Total reported value
- $5,469,771
- Reported price per share
- $8.41
- Number of holders
- 1
- Value change
- -$89,907,489
- Number of sells
- 36
Security identity
Holder snapshot
Report period
Q1 2026
Institutions
1
Top holders
1
XLO full security history
Ownership snapshot
Full 13F holder table
Previous quarter: Q4 2025
Xilio Therapeutics, Inc. SEC filings
Xilio Therapeutics, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 98422T100
Recent filing periods:
Ownership snapshot
Top reported holders of XLO - Xilio Therapeutics, Inc. - Common Stock, par value $0.0001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Lead holder
GILEAD SCIENCES, INC.
13D/G signal
GILEAD SCIENCES, INC.
Evidence rows
15
Latest as of
31 Mar 2026
3/4/5
13D/G
13F
Lead comparable stake: 20%
13D/G row: GILEAD SCIENCES, INC.
Showing 1-6 of 15 holder rows.
Rank 1 holder
GILEAD SCIENCES, INC.
3/4/5
13D/G
13F
- Ownership
- 20%
- Position
- $21.6M
Rank 2 holder
Bain Capital Life Sciences Fund II, L.P.
13D/G
- Ownership
- 10%
- Position
- $5.58M
Rank 3 holder
ORBIMED ADVISORS LLC
13D/G
- Ownership
- 10%
- Position
- $5.4M
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| GILEAD SCIENCES, INC. |
3/4/5
13D/G
13F
10%+ Owner · Company
|
20%
from 13D/G
|
$21,601,543
67,054,266 shares
mixed-class rows
|
+$1,999,991 | 13 Feb 2026 |
| Bain Capital Life Sciences Fund II, L.P. |
13D/G
BCLS II Equity Opportunities, LP
|
10%
|
$5,584,417
664,021 shares
|
-$47,060,014 | 31 Mar 2026 |
| ORBIMED ADVISORS LLC |
13D/G
|
10%
|
$5,399,220
642,000 shares
|
$0 | 31 Mar 2026 |
| Coastlands Capital LP |
13D/G
|
10%
|
$3,742,248
5,346,069 shares
|
$0 | 04 Dec 2025 |
| Sirenia Capital Management LP |
13D/G
|
9.9%
|
$9,611,469
1,142,862 shares
|
$0 | 31 Mar 2026 |
| AbbVie Inc. |
13D/G
|
9%
|
$3,304,348
4,347,826 shares
|
$0 | 11 Feb 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q1 2026
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
1
Shares
650,389
Rows available
1
| Investor | Option | Weight % | Change % | Reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* Reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that failed the local validity check.
Compare Q1 2026 vs Q4 2025 Across Filers
Q4 2025 holders
37
Q1 2026 holders
1
Holder diff
-36
| Investor | Q4 2025 Shares | Q1 2026 Shares | Share Diff | Share Chg % | Q4 2025 value | Q1 2026 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend